FluoroPharma Medical, Inc.
FPMI · OTC
12/31/2016 | 9/30/2016 | 6/30/2016 | 3/31/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.03 | 0.05 | -0.07 |
| FCF Yield | -3.06% | -8.64% | 2.08% | -4.76% |
| EV / EBITDA | -18.88 | -38.06 | -18.94 | -19.76 |
| Quality | ||||
| ROIC | 6.99% | 4.48% | 9.05% | 15.44% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | -1.38 | -0.22 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 78.07% | -431.34% | 140.62% | 59.57% |
| Safety | ||||
| Net Debt / EBITDA | -11.41 | -18.17 | -7.44 | -7.45 |
| Interest Coverage | -2.65 | -1.50 | -1.49 | -1.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |